ICGC

ICGC
Name	International Cancer Genome Consortium
Abbreviation	ICGC
Formation	2008
Type	International research consortium
Headquarters	Toronto, Ontario, Canada
Region served	International

ICGC is a multinational scientific consortium focused on comprehensive characterization of genomic, transcriptomic, and epigenomic changes in human cancer. Founded to coordinate large-scale sequencing efforts, the consortium brought together research centers, funding agencies, and patient groups to generate standardized cancer genome datasets, enabling comparative analyses across tumor types and populations.

Overview

The consortium coordinated projects across continents linking institutions such as Ontario Institute for Cancer Research, Wellcome Trust Sanger Institute, Broad Institute, European Bioinformatics Institute, Genome Institute of Singapore, Beijing Genomics Institute, RIKEN, Institut Curie, Dana-Farber Cancer Institute, MD Anderson Cancer Center, Memorial Sloan Kettering Cancer Center, Yale School of Medicine, Cold Spring Harbor Laboratory, Peter MacCallum Cancer Centre, University of Tokyo Hospital, Seoul National University Hospital, Karolinska Institutet, Max Planck Institute for Molecular Genetics, Institut Pasteur, Spanish National Cancer Research Centre, Francis Crick Institute, Swiss Institute of Bioinformatics, Garvan Institute of Medical Research, University of Cambridge, Harvard Medical School, Stanford University School of Medicine, University College London, McGill University, University of Melbourne, Monash University, University of Oxford, University of British Columbia, University of California, San Francisco, Yokohama City University, Vanderbilt University Medical Center, Johns Hopkins University, Imperial College London, Technical University of Munich, The Chinese University of Hong Kong, National Cancer Center Hospital (Japan), MRC Clinical Sciences Centre, University of Sydney, Trinity College Dublin, University of Toronto and Peking University Health Science Center with funders including Cancer Research UK, Canadian Institutes of Health Research, National Institutes of Health, European Commission, Japan Agency for Medical Research and Development, National Natural Science Foundation of China, Wellcome Trust, Australian National Health and Medical Research Council, Fondation ARC.

History

The initiative launched in 2008 following meetings that involved stakeholders from Human Genome Project, Cancer Genome Atlas, European Molecular Biology Laboratory, International Agency for Research on Cancer, World Health Organization, Organisation for Economic Co-operation and Development, Group on Earth Observations, Global Alliance for Genomics and Health, International Rare Diseases Research Consortium, Bill & Melinda Gates Foundation and national funding bodies. Early milestones included coordination with The Cancer Genome Atlas and harmonization of standards inspired by Sequence Read Archive and GenBank. Major project rollouts targeted tumor types listed by centers such as Memorial Sloan Kettering Cancer Center and MD Anderson Cancer Center and were discussed at conferences including American Association for Cancer Research, European Society for Medical Oncology, ASCO Annual Meeting, Bioinformatics Open Days and Genome Informatics Workshop.

Organization and governance

Governance involved an international board comprising representatives from Ontario Institute for Cancer Research, Wellcome Trust Sanger Institute, Broad Institute, European Bioinformatics Institute, Institut Curie, RIKEN, Beijing Genomics Institute and national funders like Cancer Research UK and National Institutes of Health. Scientific committees coordinated ethics and policy aligning with guidelines from International Committee of Medical Journal Editors, Declaration of Helsinki, Council of Europe, European Commission Ethics Directorate-General, UNESCO and World Medical Association. Data access policies were informed by frameworks used by dbGaP, European Genome-phenome Archive, Genomic Data Commons and standards from Global Alliance for Genomics and Health. Collaborative agreements referenced practices at Wellcome Trust, Gates Foundation and National Cancer Institute.

Research programs and projects

Programs spanned whole-genome sequencing, exome sequencing, transcriptome profiling and epigenetic mapping across cancers such as those cataloged by International Agency for Research on Cancer and tumor repositories at Clinical Proteomic Tumor Analysis Consortium, The Cancer Genome Atlas, Pediatric Cancer Genome Project, UK Biobank, European Prospective Investigation into Cancer and Nutrition, China Kadoorie Biobank and national cancer registries like SEER Program. Projects targeted malignancies including breast, lung, colorectal, pancreatic, prostate, glioblastoma, leukemia and rarer tumors with laboratories at Broad Institute, Wellcome Trust Sanger Institute, Institut Curie, RIKEN, Beijing Genomics Institute, Genome Institute of Singapore and Dana-Farber Cancer Institute contributing. Analytical collaborations involved groups from European Bioinformatics Institute, Swiss Institute of Bioinformatics, Cold Spring Harbor Laboratory, Stanford University School of Medicine and Harvard Medical School.

Data resources and accessibility

The consortium produced datasets deposited in repositories such as European Genome-phenome Archive, GenBank, Sequence Read Archive, ArrayExpress, Gene Expression Omnibus, Genomic Data Commons and was cataloged by aggregators like cBioPortal, UCSC Genome Browser, Ensembl, COSMIC, dbGaP, ICGC Data Portal (note: portal name descriptive). Access models followed controlled-access paradigms similar to dbGaP and open-access matrices used by European Nucleotide Archive. Metadata standards aligned with MIAME and ontologies used by Human Phenotype Ontology, SNOMED CT, ICD-10 and HGNC gene nomenclature systems.

Key findings and impact

Consortium outputs elucidated mutational landscapes and driver events reported alongside work from The Cancer Genome Atlas, influencing clinical translation at centers like Memorial Sloan Kettering Cancer Center, Dana-Farber Cancer Institute, MD Anderson Cancer Center and informing targeted therapy research at Roche, Novartis, Pfizer, AstraZeneca, Merck & Co., Bristol-Myers Squibb, GlaxoSmithKline and biotech firms such as Illumina, Thermo Fisher Scientific, PacBio, Oxford Nanopore Technologies, Foundation Medicine and Guardant Health. Key scientific papers appeared in journals including Nature, Science, Nature Genetics, Cell, Genome Research and The Lancet Oncology. Findings contributed to biomarker discovery, mutational signature analysis connecting to work by Alexandrov et al., and influenced regulatory submissions to agencies like U.S. Food and Drug Administration, European Medicines Agency and national health technology assessment bodies.

Criticisms and controversies

Critiques centered on data access, privacy and equity debated against standards from Declaration of Helsinki, GDPR and policies advocated by Global Alliance for Genomics and Health and UNESCO. Concerns involved representation of populations compared to efforts like 1000 Genomes Project, UK Biobank, China Kadoorie Biobank and All of Us Research Program, and questions about consent models referenced cases reviewed by National Institutes of Health and ethical discussions at American Society of Human Genetics meetings. Debates also engaged journals such as Nature, Science and PLOS Medicine over data sharing, reproducibility issues highlighted by groups at Cold Spring Harbor Laboratory and Stanford University School of Medicine, and resource allocation assessed by panels convened at World Health Organization and Organisation for Economic Co-operation and Development forums.

Category:Genomics